Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity in wistar rats  by Warpe, Vikas S. et al.
Available online at www.sciencedirect.comScienceDirect
Journal of Acute Medicine 5 (2015) 1e8
www.e-jacme.comOriginal Research
Cardioprotective effect of ellagic acid on doxorubicin induced cardiotoxicity
in wistar rats
Vikas S. Warpe 1, Vishal R. Mali 1, Arulmozhi S 1,*, Subhash L. Bodhankar 1,
Kakasaheb R. Mahadik 2
1 Department of Pharmacology, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune 411 038, Maharashtra, India
2 Department of Pharmaceutical Chemistry, Bharati Vidyapeeth University, Poona College of Pharmacy, Erandwane, Pune 411 038, Maharashtra, India
Received 27 June 2014; accepted 17 February 2015
Available online 3 April 2015AbstractBackground/Aim: The objective of the study was to evaluate the cardioprotective activity of ellagic acid in doxorubicin induced cardiotoxicity.
Methods: Male wistar rats (180e220 g) were divided in to four groups: vehicle control, doxorubicin control, ellagic acid (100 mg/kg) and ellagic
acid (200 mg/kg). Doxorubicin was administered to all the groups except vehicle control at a dose of 3.75 mg/kg at week 2,3,4,5 to make a
cumulative dose of 3.75 mg/kg. Ellagic acid was administered to the respective group of animals at a dose of 100 mg/kg 200 mg/kg, respectively
once daily orally for 6 weeks. On the last day of the study, blood was collected by retro-orbital puncture and LDH and CK-MB were estimated.
The animals were cannulated and the ECG and hemodynamic parameters were recorded. The animals were then sacrificed and histology of heart
was performed.
Results: Doxorubicin showed cardiotoxicity manifested by changes in serum marker enzymes, ECG and hemodynamic parameters which was
further confirmed by histology of heart. This doxorubicin induced changes were attenuated by treatment with ellagic acid (200 mg/kg).
Conclusion: It has been concluded that ellagic acid (200 mg/kg) treatment for 6 weeks protects the heart of rats in doxorubicin induced car-
diotoxicity.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Doxorubicin is an anticancer drug which belongs to
anthracycline antibiotics and is being used widely for treat-
ment of various hematological and solid tumor malignancies
including breast cancer, leukemia, and sarcomas.1,2 However,
its clinical uses are limited by dose-dependent side effect of
cardiotoxicity, which may lead to irreversible cardiomyopathy
and eventually heart failure.3,4 The incidence of doxorubicin-* Corresponding author. Department of Pharmacology, Bharati Vidyapeeth
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2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. Publishedrelated cardiotoxicity increases sharply above a cumulative
dose of 550 mg/m2 body surface area. So, the maximum
recommended cumulative dose of Doxorubicin was tentatively
set at 500 or 450 mg/square meters.5 Doxorubicin induced
cardiotoxicity is mediated through different mechanisms
including free radical production, calcium overloading, mito-
chondrial dysfunction and peroxynitrite formation have been
proposed.6e8 Doxorubicin is enzymatically reduced to its
semiquinone radical.9 This Doxorubicin semiquinone radical
directly transfers its electron to molecular oxygen, generating
a superoxide radical and hydrogen peroxide.10 As reactive
oxygen species (ROS) play important roles in Doxorubicin-
induced toxicity. Many compounds with antioxidant proper-
ties have been examined as potential therapeutic and/orby Elsevier Taiwan LLC. All rights reserved.
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p-coumaric acid,12 Withania somnifera,13 Lycium barbarum,14
Catechin15 and carvedilol.16
In recent years, polyphenols have attracted considerable
attention as agents that protect cells or molecules from
oxidative myocardial injury. Ellagic acid is polyphenolic
phytonutrient found in wide varieties of berries and nuts, and it
has received particular attention because of its extensive array
of biological properties. Previous studies indicated that ellagic
acid showed free radical scavenging action, chemopreventive,
antiopoptic, anti-inflammatory, anti-cataractogenetic, car-
dioprotective, gastroprotective, ulcer healing, antifibrotic,
antidiabetic, hypolipidemic, antiatherosclerotic and estro-
genic/antiestrogenic properties.17e30
Polyphenols are excellent cadioprotectants. Hence, we hy-
pothesized that ellagic acid may have a cardioprotective effect.
The objective of the present studywas designed to investigate the
protective effect of the oral pretreatment of ellagic acid on
experimentally inducedmyocardial infarction inWistar rats. This
study also attempted to explain the possible mechanism of the
ellagic acid, by studying the electro cardiological, hemodynamic,
biochemical changes in doxorubicin induced cardiotoxicity.
2. Methods2.1. Drugs and chemicalsEllagic acid and doxorubicin were purchased from Sigma
Chemical Co., St. Louis MO, USA, urethane (Hi-Media
Laboratories Mumbai), anesthetic ether (Narson Pharma),-
formaldehyde solution (35% formalin) (Merck Ltd), heparin
(Gland Pharma Ltd) and normal saline (Baxter Ltd) were
purchased from respective vendors. All other chemicals used
in this study were of analytical grade.2.2. Experimental animalsAll the experiments were carried out with male Wistar rats
aged 3e4 months, weighing 180e220 g, purchased from the
National Institute of Bioscience, Pune, They were housed in
polypropylene cages (47  34  20 cm) lined with husk,
renewed every 24 hours under a 12-hour light/dark cycle at
around 22C with 50% humidity. The rats had free access to
water. The rats were fed on a standard pellet diet (Chakan oil
mills, Pune, Maharashtra, India) once a day. The experimental
protocol was approved by the Institutional Animal Ethics
Committee (IAEC) constituted in accordance with the rules
and guidelines of the Committee for the Purpose of Control
and Supervision on Experimental Animals (CPCSEA), India.2.3. Experimental design and protocolA total of 24 animals were randomly divided into four
groups comprising of six animals per group.
Group I: control group, received 2% gum acacia as a vehicle
for 42 days and normal saline (i.p) on day 14, 21, 28 and 35.Group II: received Doxorubicin in normal saline (3.750 mg/
kg) i.p on day 14, 21, 28 and 35 to reach total cumulative
dose (15 mg/kg).
Group III: received ellagic acid (100 mg/kg p.o) in 2% gum
acacia for 42 days and then doxorubicin in normal saline
(3.750 mg/kg) i.p on day 14, 21, 28 and 35 to reach total
cumulative dose (15 mg/kg).
Group IV: received ellagic acid (200 mg/kg p.o) in 2% gum
acacia for 42 days and then doxorubicin in normal saline
(3.750 mg/kg) i.p on day 14, 21, 28 and 35 to reach total
cumulative dose (15 mg/kg).2.4. Serum parametersOne week after the last i.p injection of doxorubicin (day 42,
168 hours from last dose of doxorubicin), blood was collected
from the retro-orbital plexus of each rat under mild ether
anesthesia (Narson Pharma, India) for determination of
biochemical parameters. Serum was separated in a cryocen-
trifuge (Eppendroff, India) at 4C at 7000 rpm for 15 minutes
and lactate dehydrogenase (LDH), creatine phosphokinase-
MB isoenzyme (CK-MB) were measured by using standard
kits according to the manufacturer's instruction manual (Merck
Specialities Pvt. Ltd. India) using an autoanalyzer (Nihon
Kohden, Japan).2.5. ElectrocardiogramECG was recorded before beginning of treatment and 1
week after the last doxorubicin injection, the electrocardio-
graph patterns were recorded by an eight-channel PowerLab
(ADInstruments, Bella Vista, New South Wales, Australia)
running LabChart Pro 7 software (ADInstruments). The types
of alterations (QT interval, ST-segment elevation and QRS
complex) in the experimental rats were recorded.2.6. Hemodynamic parametersOneweek after the last i.p doxorubicin injection animalswere
anesthetized by urethane (1.25 g/kg). The right carotid artery of
each rat was cannulated for the measurement of heart rate (HR),
systolic blood pressure (SBP), diastolic blood pressure (DBP)
andmean aterial blood pressure (MABP). The cannulawas filled
with heparinised saline and connected to pressure transducer.
The hemodynamic parameters were recorded by an eight-
channel PowerLab (ADInstruments) running LabChart Pro 7
software (ADInstruments). Left ventricular systolic pressure
wasmeasured bymeans of aMillarmikro-tip transducer catheter
inserted into the left ventricle via the right carotid artery and
connected to a BM 614r2 amplifier (ADInstruments). dp/dtMax,
dp/dt Min and LVSP signals were obtained from primary signals
by means of an acquisition data system (ADInstruments) All the
above signals were continuously recorded by means of the
acquisition data system indicated above.
After recording of hemodynamic parameters, the animals
were euthanized, and the heart was removed. A section of
heart was homogenized in Tris-HCl buffer and
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catalase were determined.11 The other section was placed in
10% formalin solution for histopathology.2.7. Antioxidant parameters
2.7.1. Measurement of TBARS
The Thiobarbituric acid-reactive substance was measured as
a marker of lipid peroxidation in the pancreas. The homoge-
nized pancreatic tissue was added to 1.5 ml of 8.1% sodium
dodecyl sulphate, 1.5 ml of 20% acetate buffer (pH 3.5) and
1.5 ml of 0.8% TBA (Thiobarbituric acid) solution. Themixture
was heated at 95C for 1 hour. After cooling, 5 ml of n-butanol-
pyridine (14:1) was added for extraction and the absorbance of
n-butanol-pyridine layer at 532 nm (Schimadzu UV-Vis 1700)
was measured for determination of TBA reactive substance.11
2.7.2. Determination of glutathione
An aliquot of pancreatic tissue homogenate supernatant
(0.4 ml) was added to dark polyethylene tube containing
1.6 ml of 0.4 M Tris e EDTA buffer, pH 8.9. After vortex-
mixing, 40 ml of 10 mM dithiobisnitrobenzoic acid in meth-
anol was added. The samples were vortex-mixed again and the
absorbance at 412 nm was read after 5 minutes (Schimadzu
UV-Vis 1700). The values of unknown samples were drawn
from a standard curve plotted by assaying different known
concentrations of glutathione (GSH). The amount of GSH was
expressed as mmol/g of protein.11
2.7.3. Measurement of superoxide dismutase (SOD)
Total SOD activity was measured by determining the
ability to inhibit the auto-oxidation of pyrogallol. The rate of
auto-oxidation was determined by measuring increases in the
absorbance at 420 nm. Reaction mixture containing 0.2 mM
pyrogallol in 50 mM Tris-cacodylic acid buffer (pH 8.5) and
1 mM diethylene triamine penta acetic acid was incubated for
90 seconds at 25C. One unit of SOD activity is defined as the
amount of the enzyme required to inhibit the rate of pyrogallol
auto-oxidation by 50%.11
2.7.4. Measurement of catalase (CAT)
CAT activity was assayed with hydrogen peroxide as the
substrate using a method based on the direct measurement of
H2O2 decomposition. CAT activity was determined by
measuring the exponential disappearance of H2O2 at 240 nm
and expressed as units/mg of protein as described by Aebi.
The final volume of each enzyme assay was 3 ml of substrate
and 20 ml of the supernatant of pancreatic tissue homogenate.
The assay was performed at 25C and measured at 240 nm.
Enzyme activity was expressed as units per gram of protein,
and one unit of CAT activity represented 1 mmol H2O2
decomposed per minute.11Fig. 1. Effect of ellagic acid (100 and 200 mg/kg) on heart weight to body2.8. Histopathology
weight ratio in doxorubicin induced cardiotoxicity of Wistar rats. Values are
expressed as mean ± SEM (n ¼ 6), one-way ANOVA followed by Tukey's
multiple comparison test. c p < 0.01 as compared to vehicle control group,
*p < 0.05 as compared to doxorubicin group.The organ specimens were subjected to dehydration with
xylene (1 hour each) and alcohol of 70%, 90% and 100%strength each for 2 hours. The infiltration and impregnation was
carried out by treatment with paraffin wax twice for each time
for one hour. Parrafin wax was used to prepare paraffin Lmolds.
Specimens were cut into sections of 3e5 mm thickness and
stained with hematoxylin and eosin. The sections were mounted
by diestrene phthalate xylene. The parameters of histopathology
assessment of heart sections were hyperemia, cellular infiltra-
tion and necrosis. The grading system used for assessment of
parameters was (e: absence of change; þ: 0e25% area shows
changes; þþ: 25e50% area shows changes; þþþ: 50 -75%;
þþþþ:75e100% area shows changes).2.9. Statistical analysisData were expressed as the mean ± SEM of six values.
Statistical analysis was carried out by one-way ANOVA fol-
lowed by Tukey's multiple comparison test using GraphPad
Prism 5.00 for Windows (GraphPad Software Inc., La Jolla,
CA, USA). The p value was considered significant when
p < 0.05.
3. Result3.1. Heart weight to body weight ratioThe doxorubicin treated rats showed a significant decrease
the heart weight to body weight ratio (p < 0.001) when
compared to vehicle control group. On oral treatment with
ellagic acid at 200 mg/kg for a period of 42 days significantly
increased the heart weight to body weight ratio (p < 0.05)
when compared to doxorubicin group, while treatment with
ellagic acid at 100 mg/kg for a period of 42 days non-
significantly increased the heart weight to body weight ratio
when compared to doxorubicin group (Fig. 1).
Table 2
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Effect of ellagic acid on ECG parameters.
Treatment Groups
Parameters
Vehicle
Control
Doxorubicin EA
100 mg/kg 200 mg/kg
QT interval (ms) 58 ± 1.7 78 ± 2.2c 73 ± 1.7 67 ± 2.3**
ST Interval (ms) 45 ± 2.2 59 ± 2.6b 54 ± 1.4 47 ± 2.8**
QRS complex (ms) 15 ± 0.56 17 ± 0.73 16 ± 0.54 15 ± 0.59
Values are expressed as mean ± SEM (n ¼ 6), one-way ANOVA followed by
Tukey's multiple comparison test. bp < 0.01, cp < 0.001 as compared to vehicle
control group, and **p < 0.01 as compared to doxorubicin group.Table 1 shows the effect of ellagic acid on biochemical
parameters of the vehicle control and experimental rats. The
doxorubicin treated rats showed a significant (p < 0.001) in-
crease in the levels of serum creatine kinase and lactate de-
hydrogenase in the serum, when compared to the vehicle
control rats. The oral treatment with ellagic acid at 200 mg/kg
for a period of 42 days significantly (p < 0.001 and p < 0.01)
decreased the elevated level of serum creatine kinase and
lactate dehydrogenase when compared to doxorubicin group,
while oral pretreatment with ellagic acid at 100 mg/kg for a
period of 42 days non-significantly decrease the elevated level
of creatine kinase and lactate dehydrogenase in serum when
compared to doxorubicin group.3.3. Evaluation of ECG parametersTable 2 shows the effect of ellagic acid on the electrocar-
diographic changes of the vehicle control and experimental
rats. The doxorubicin treated rats showed a significant
(p < 0.001 and p < 0.01) increase in QT interval, ST segment
along with a non significant increase in QRS complex as
compared to the vehicle control group. The oral pretreatment
with ellagic acid at 200 mg/kg for a period of 42 days) showed
significant (p < 0.01) decrease in QT interval and ST segment
along with non significant decrease in QRS complex when
compared to doxorubicin treated rats, while oral pretreatment
with ellagic acid 100 mg/kg for a period of 42 days non-
significant decrease in QT, ST interval and QRS complex
when compared to doxorubicin group.3.4. Evaluation of hemodynamic parametersTable 3
Effect of ellagic acid on hemodynamic parameters.
Treatment Groups Vehicle Doxorubicin EATable 3 shows the effect of ellagic acid on the arterial blood
pressure of the vehicle control and experimental rats. The
doxorubicin treated rats showed a significant decreases in the
systolic (p < 0.01), diastolic (p < 0.05) and mean arterial
blood pressure (p < 0.01) as compared to the vehicle control
group. Oral treatment with ellagic acid at 200 mg/kg for a
period of 42 days showed a significant increase in the systolic
and mean arterial blood pressure (p < 0.05) along with non-
significant increase in diastolic blood pressure as compared
to the doxorubicin group, while treatment with ellagic acid at
100 mg/kg for a period of 42 days non-significantly increased
in the systolic, diastolic and mean arterial blood pressure asTable 1
Effect of ellagic acid on serum parameters.
Treatment Groups
Parameters
Vehicle
Control
Doxorubicin EA
100 mg/kg 200 mg/kg
CK-MB 788 ± 116 2564 ± 164c 2363 ± 186 1132 ± 201***
LDH 1688 ± 178 5598 ± 208c 5257 ± 633 2967 ± 707**
Values are expressed as mean ± SEM (n ¼ 6), one-way ANOVA followed by
Tukey's multiple comparison test. c p < 0.001 as compared to vehicle control
group, **p < 0.01, and ***p < 0.001 as compared to doxorubicin group.compared to the doxorubicin group. We observed a non sig-
nificant decrease in the heart rate of the doxorubicin group.
The oral pretreatment of ellagic acid (100 and 200 mg/kg)
non-significantly increased in reduced heart rate when
compared to the doxorubicin group. However, we also
observed dP/dt Max, dP/dt Min and LVSP (Table 3). The
doxorubicin treated rats showed significant (p < 0.05)
decrease in the dp/dt Max, dp/dt Min and LVSP when compared
to vehicle control group. Oral treatment with ellagic acid at
200 mg/kg for a period of 42 days non-significantly increased
in dP/dtMax, dP/dt Min and non-significantly (p < 0.05) increase
LVSP when compared to the doxorubicin group, while pre-
treatment with ellagic acid at 100 mg/kg for a period of 42
days non-significantly increased in dP/dt Max, dP/dt Min and
LVSP when compared to the doxorubicin group.3.5. Antioxidant parameters
3.5.1. Malondialdehyde (MDA)
There was a significant increase (p < 0.05) in the lipid
peroxidation in the doxorubicin group, which was evident with
the increase in malondialdehyde levels (MDA). Treatment
with ellagic acid (100 and 200 mg/kg) significantly (p < 0.05
and p < 0.01, respectively) decreased this elevated malon-
dialdehyde (Table 4).
3.5.2. Glutathione
There was a significant decrease (p < 0.05) in the gluta-
thione levels in the doxorubicin group when compared to the
vehicle control rats. However, treatment with ellagic acid (100Parameters Control
100 mg/kg 200 mg/kg
HR 373 ± 16 326 ± 11 331 ± 18 345 ± 26
SBP 122 ± 4.5 90 ± 5.4b 98 ± 6.7 115 ± 4.8*
DBP 86 ± 6.4 62 ± 5.9a 69 ± 5.9 83 ± 3.5
MABP 106 ± 4.9 79 ± 5.6b 86 ± 5.9 102 ± 3.8*
dP/dt Max 2808 ± 192 1232 ± 101
c 1290 ± 65 1676 ± 141
dP/dt Min 684 ± 65 451 ± 26
a 506 ± 47 624 ± 69
LVSP 116 ± 4.2 93 ± 4.0a 99 ± 5.0 112 ± 5.4*
Values are expressed as mean ± SEM (n ¼ 6), one-way ANOVA followed by
Tukey's multiple comparison test.a p < 0.05, b p < 0.01 and cp < 0.001 as
compared to vehicle control group, *p < 0.05 as compared to doxorubicin
group.
Table 4
Effect of ellagic acid on antioxidant parameters.
Treatment Groups Parameters Vehicle Control Doxorubicin EA
100 mg/kg 200 mg/kg
MDA (nmol/g of protein) 37.4 ± 1.6 127.2 ± 3.12a 83.1 ± 1.8* 44.35 ± 2.6**
GSH (mmol/g protein) 4.54 ± 0.25 1.52 ± 0.08a 2.94 ± 0.62* 3.48 ± 0.12**
SOD (U/mg protein) 34.52 ± 1.4 15.52 ± 2.9a 21.32 ± 1.42** 25.36 ± 1.58**
Catalase (U/mg protein) 8.26 ± 0.24 2.42 ± 0.62a 5.38 ± 0.36** 6.22 ± 0.48**
Values are expressed as mean ± SEM (n ¼ 6), one-way ANOVA followed by Tukey's multiple comparison test.a p < 0.05, b p < 0.01 and c p < 0.001 as compared
to vehicle control group, *p < 0.05 and **p < 0.01 as compared to doxorubicin group.
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respectively) these levels (Table 4).
3.5.3. Superoxide dismutase
There was a significant decrease (p< 0.05) in the superoxide
dismutase levels in the doxorubicin group when compared to
the vehicle control rats. However, treatment with ellagic acid
significantly increased (p < 0.01) these levels (Table 4), which
validates the antioxidant property of ellagic acid.
3.5.4. Catalase
There was a significant decrease (p < 0.05) in the catalase
levels in the doxorubicin group when compared to the vehicle
control rats. However, treatment with ellagic acid significantly
increased (p < 0.01) these levels (Table 4), which validates the
antioxidant property of ellagic acid.3.6. HistopathologyFig. 2 illustrates the section of heart tissue in vehicle control
rats (A), rats that received Doxorubicin only (B), rats that
received Doxorubicin þ EA (100 mg/kg) (C) and rats that
received Doxorubicinþ EA (200 mg/kg) The histopathology of
the heart of the vehicle control group showed absence of hy-
peremia, cellular infiltration and necrosis (graded as  :
absence of changes). Doxorubicin administration in the doxo-
rubicin group showed hyperemia (þþ), cellular infiltration
(þþþþ) and necrosis (þþþþ) which means that hypermia
occurred in 25e50% area of the rat heart, cellular infiltration
and necrosis occurred in a 75e100% area of heart and Cellular
infiltration and necrosis in large areas of the heart confirmed
cardiotoxicity in rats. On the other hand, hyperaemia(þ),
cellular infiltration(þþ) and necrosis(þþþ) were observed in
a area of the heart (þ, 0e25%; þþ,25-50%; þþþ,50-75%) in
Doxorubicin þ EA (200 mg/kg). while hyperemia (þþ),
cellular infiltration (þþþ) and necrosis (þþþþ) were
observed in area of heart (þþ,25-50%; þþþ,50-75%;
þþþþ,75-100%) in Doxorubicin þ EA (100 mg/kg). The
results of histopathological analysis thus indicated that the rat
heart was partially protected by pre-treatment with in EA
(200 mg/kg) against doxorubicin-induced cardiotoxicity.
4. Discussion
The present study deals with the effect of ellagic acid in
doxorubicin induced cardiotoxicity. Doxorubicin has beenreported to cause cardiomyopathy in various animal spe-
cies.16,29e31 Doxorubicin induced cardiotoxicity and oxidative
stress has been confirmed in many experimental models. There
is a prominent role of ROS including hydroxyl radical in
doxorubicin induced cardiotoxicity. Doxorubicin is converted
in the cardiac tissue into its semiquinone form, which is a
toxic, short lived metabolite that interacts with molecular
oxygen and initiates a cascade of reaction leading to ROS
generation.32 The other reported mechanism of doxorubicin
induced stress is the formation of an anthracycline-iron
(Fe2þ) free radical complex.33 The latter reacts with
hydrogen peroxide to produce (OH۰) radical. ROS react with
lipids, protein and other cellular constituents causing damage
to mitochondria and cell membranes of the heart muscle
cells.34
The cardiac biomarker enzymes CK-MB and LDH are
extensively used in the clinical practice as markers for the
diagnosis of cardiac toxicity. Doxorubicin induces marked
cardiotoxicity which was demonstrated by increase in CK-MB
and LDH activities. Treatment with EA significantly pre-
vented these increases and reversed doxorubicin induced hy-
potension and bradycardia. The magnitude of CK-MB and
LDH activities in blood after myocardial injury reflects the
extend of damage in its musculature.35 This was further
confirmed by the histopathological changes in the heart
including the fibrosis, apoptosis, loss of striation and inflam-
matory cells.
Treatment with doxorubicin resulted not only in mechani-
cal dysfunction of the heart but also in inhomogeneity of
ventricular depolorisation and repolarisation reflected by the
occurrence of changes in the ECG. The observed ECG
changes included prolongation of the ST segment, QRS in-
tervals and QT interval. The cardiac dysfunction was also
manifested by ECG changes, altered plasma levels of cardiac
injury markers and histopathological changes in cardiac
muscle along with decreased LVSP and decreased max and
min dp/dt.36 Prolonged administration of doxorubicin caused
decrease in heart rate, these result was consistent with earlier
studies where it was hypothesized that reactive oxygen species
generation may cause disturbance in calcium homeostasis.
This could lead to reduction in heart rate because decrease in
intracellular calcium induced reduced excitability of pace-
maker cells in the SA node and other cells in the cardiac
conducting system. Doxorubicin is an inhibitor of both sys-
tolic and diastolic cardiac function. Furthermore, its metabo-
lite was more potent inhibitor than doxorubicin on the ion
Fig. 2. Histopathology of the heart. (A) Microscopic section of vehicle control group rat heart showing normal architecture of cardiac muscle. (B) Microscopic
section of doxorubicin-induced group rat heart showing infiltration of inflammatory cells, necrosis and hyperemia in cardiac muscle fiber. (C) Microscopic section
of ellagic acid (100 mg/kg) treated doxorubicin-induced group rat heart showing infiltration of inflammatory cells, necrosis and hyperemia in cardiac muscle fiber.
(D) Microscopic section of ellagic acid (200 mg/kg) treated doxorubicin-induced group rat heart showing less infiltration of inflammatory cells, necrosis and
hyperemia in cardiac muscle fiber.
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activity of cardiac sarcoplasmic reticulum vesicle.37 Hence,
LVSP, dp/dt max and dp/dt min are the direct indicators of
cardiac systolic and diastolic function.38 In the present study,
treatment with EA significantly attenuated the ST interval
prolongation which shows that the cardiomyocyte injury was
attenuated and the left ventricular function was preserved.39
Treatment with EA significantly reversed the LVSP which
indicate that the cardiac function increased significantly.
However, there was no significant difference observed with
EA on max dp/dt and min dp/dt, which indicate that the heart
rate was not affected.
Doxorubicin also caused a significant decrease in heart
weight and heart body weight ration which indicate loss of
myofibrils and myocardial necrosis.39 This is in line with the
previous findings11,40. Reduction of body weight, debilitation
and death associated with multiple, long administration of
DOX in experimental animals, are considered multifactorial.
These are the results of direct toxic effects on intestinal mu-
cosa appearing as mucositis, as well as additional indirect
action on the gastrointestinal tract arising from reduced food
intake causing a decrease in secretion of enteral hormones and
resulting in decreased trophic effects to the mucosa.41 This
suggestion is in accordance with the histopathological obser-
vations which are in accordance with the histopathologicalobservations which revealed myocardial coagulation necrosis
with fibrosis, vascular congestion as well as mononuclear
infiltration. Treatment with EA decreased these necrosis,
coagulation and fibrosis which further confirm the car-
dioprotective effect of EA.
Clinical and experimental investigations also suggested that
increased oxidative stress plays a role in cardiomyopathy in
heart failure associated with doxorubicin.11 There was a sig-
nificant increase in the MDA, decrease in the GSH, CAT and
SOD following doxorubicin administration when compared to
vehicle control group. This clearly indicate the oxidative stress
on the heart treated with doxorubicin. The observed GSH
deficiency is due to GSH consumption in the interactions of
DOX-induced free radicals with bio-membrane and the sub-
sequent lipid peroxidation.11 Our studies observe the increased
GSH, SOD and catalyse, which is because of the antioxidant
property of ellagic acid which has inhibited the oxidative
process in the heart.
5. Conclusion
In the present study, EA (200 mg/kg) is proven to have a
cardioprotective effect in doxorubicin induced cardiotoxicity.
This study suggests a possible usefulness of EA as a car-
dioprotective agent contributing to a safer use of doxorubicin
7V.S. Warpe et al. / Journal of Acute Medicine 5 (2015) 1e8in patient subjected to chemotherapy. However, car-
dioprotective effect was observed only in the higher dose of
EA. Further dose response and bioavailability studies are
needed to prove the efficacy of EA as a cardioprotective drug.
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